GET DAILY SIGNALSSyndax Pharmaceuticals (SNDX): Weighing the Odds of Hitting the $41 Price Target
Key Takeaways
- The $41 central target is the arithmetic mean of nine verified analyst price targets, which range from $23 to $57.
- Shares closed at $16.55 on October 12, 2026, and fell roughly 15% in after-hours trading after a Phase 2 trial miss; reaching $41 implies a move of about 148% from that close.
- Every covering analyst rates the stock Buy or Overweight, reflecting a Strong Buy consensus view.
- Key supports are Revuforj's expanded label, rising product revenue, and the Niktimvo cGVHD franchise.
- Principal risks include the loss of IPF optionality, a Revuforj boxed warning, heavy cash burn, and elevated short interest near 26% of float.
Analyst Price Targets and Consensus View
Nine individual targets inform the $41 average analyst price target: Citi ($57), BTIG ($56), Mizuho ($45), Stifel ($40), J.P. Morgan ($40), H.C. Wainwright ($38), Barclays ($37), UBS ($33), and Bank of America ($23). The arithmetic mean is $41, but the wide $23–$57 range signals genuine disagreement about how quickly the oncology franchise scales.
Bullish firms such as Citi and BTIG emphasize SNDX's Revuforj expansion into a larger relapsed/refractory acute myeloid leukemia (AML) population. Citi reiterated its $57 target after the October 2026 Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed its primary endpoint, arguing IPF was never in its model. H.C. Wainwright likewise kept its $38 target. In contrast, Bank of America lowered its target to $23 from $26, while maintaining Buy, seeing limited read-through but remaining focused on Revuforj share capture. No firm carries a Sell or Hold rating, so the dispersion reflects valuation and execution assumptions rather than disagreement over direction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At the October 12, 2026 close of $16.55, reaching $41 requires a rise of roughly 148% — a very large move. From the depressed after-hours level near $14, the implied upside is even larger. The path hinges on converting label expansion into durable revenue growth. In November 2025 the FDA expanded Revuforj's approval to relapsed/refractory mNPM1-mutated AML, and analysts see the drug competing across relapsed/refractory, post-transplant, and frontline settings. Niktimvo's cGVHD franchise continues with combination trials in earlier lines of therapy, with data expected later in 2026 and in early 2028. Still, the company is unprofitable, with trailing twelve-month EPS (earnings per share) around negative $2.52, so valuation support must come from revenue scaling toward profitability.
What Could Support a Move Toward the Target
Expanded Revuforj approval into mNPM1 AML enlarges the addressable market beyond KMT2A-rearranged disease. Product revenue is growing from a low base — consensus projected roughly $318 million in 2026 revenue, up about 26% year over year — and the Niktimvo cGVHD opportunity adds a second commercial pillar. Analysts' uniformly Buy/Overweight stance, combined with a supportive regulatory pathway and pipeline catalysts in earlier treatment lines, provides the fundamental case underpinning the higher targets. From what I see, monitoring prescription trends here will be key.
What Could Prevent the Target From Being Reached
The October 2026 IPF failure removed what bulls had called "upside optionality," sharpening focus on the two existing franchises. Revuforj carries a boxed warning for QT prolongation, which some analysts warn could temper prescribing. The company burns roughly $400 million annually in research, development, and selling costs against a still-modest revenue base, and short interest near 26% of float signals significant skepticism. Competition in AML, execution risk on launches, and any further safety or efficacy setback could compress the multiple that higher targets imply.
Technical Levels and Market Structure
The stock trades within a 52-week range of roughly $12.99 to $25.59. The $13 area near the 52-week low and the recent after-hours trough near $13.80 are near-term support levels to watch, while the $25.59 prior high and the psychological $25 level mark the first major resistance zone before any move toward $41. The post-miss selloff pushed shares below the $18–$19 zone that had acted as recent support, leaving the technical structure weakened in the short term. I ran a quick scan with Tickeron’s AI Pattern Search Engine to confirm the current resistance levels.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may use different models. Upcoming items to watch include the next quarterly report (expected around late October to early November 2026), Revuforj launch and prescription trends, cGVHD frontline trial data expected later in 2026 and in early 2028, any further label or safety updates, and analyst target revisions following the IPF decision.
Incorporating AI Signals Into My Research
In my own trading routine, I find the AI Daily Buy/Sell Signals from Tickeron helpful for monitoring names like SNDX. The tool applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps me discover opportunities, monitor existing positions, and spot shifting trends more efficiently without replacing my fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
SNDX sees MACD Histogram just turned negative
SNDX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 34 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 220 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (56.421) is normal, around the industry mean (3.498). P/E Ratio (-3.801) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals for novel cancer therapies
Industry Biotechnology
Advertisement